Roche’s Alecensa has shown strong results in two studies looking at its benefits in ALK positive non-small cell lung cancer (NSCLC) patients, both in first line use and a second line setting.
Status of immunotherapies in non-small cell lung cancer (NSCLC).
Immunotherapy combinations will be the focus – but attention is shifting towards these agents proving their overall survival benefits.
Roche rival has Breakthrough Therapy status.
Alecensa part of Roche’s goal of becoming dominant player in NSCLC